HC Wainwright Has Strong Forecast for PRQR FY2030 Earnings

ProQR Therapeutics N.V. (NASDAQ:PRQR) – Investment analysts at HC Wainwright lifted their FY2030 earnings per share (EPS) estimates for shares of ProQR Therapeutics in a report released on Monday, August 17th. HC Wainwright analyst A. Ghosh now anticipates that the biopharmaceutical company will post earnings per share of $0.20 for the year, up from their previous estimate of $0.18. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.52) per share.

PRQR has been the topic of a number of other research reports. JonesTrading lowered their target price on ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, June 26th. Chardan Capital reduced their price target on ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, June 26th. Wall Street Zen raised ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings upgraded ProQR Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Finally, Citigroup reaffirmed a “market outperform” rating on shares of ProQR Therapeutics in a research note on Wednesday, May 27th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, ProQR Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $7.33.

ProQR Therapeutics Stock Performance

NASDAQ PRQR opened at $1.93 on Tuesday. The stock has a 50-day simple moving average of $1.75 and a two-hundred day simple moving average of $1.66. The firm has a market capitalization of $203.35 million, a P/E ratio of -4.20 and a beta of 0.07. ProQR Therapeutics has a fifty-two week low of $1.33 and a fifty-two week high of $3.10.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Osaic Holdings Inc. raised its stake in shares of ProQR Therapeutics by 59.6% during the 2nd quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 4,500 shares during the period. Persistent Asset Partners Ltd grew its stake in ProQR Therapeutics by 24.5% in the 4th quarter. Persistent Asset Partners Ltd now owns 45,154 shares of the biopharmaceutical company’s stock valued at $91,000 after acquiring an additional 8,874 shares during the period. Diadema Partners LP grew its stake in ProQR Therapeutics by 6.2% in the 4th quarter. Diadema Partners LP now owns 167,532 shares of the biopharmaceutical company’s stock valued at $338,000 after acquiring an additional 9,838 shares during the period. Bank of America Corp DE increased its holdings in ProQR Therapeutics by 6.4% in the 1st quarter. Bank of America Corp DE now owns 185,110 shares of the biopharmaceutical company’s stock worth $300,000 after acquiring an additional 11,186 shares in the last quarter. Finally, Raymond James Financial Inc. increased its holdings in ProQR Therapeutics by 15.2% in the 3rd quarter. Raymond James Financial Inc. now owns 110,270 shares of the biopharmaceutical company’s stock worth $235,000 after acquiring an additional 14,549 shares in the last quarter. 32.65% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other ProQR Therapeutics news, CEO Boer Daniel Anton De purchased 150,000 shares of the business’s stock in a transaction that occurred on Thursday, July 9th. The stock was purchased at an average price of $1.74 per share, for a total transaction of $261,000.00. Following the purchase, the chief executive officer directly owned 300,000 shares in the company, valued at approximately $522,000. This trade represents a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bart Filius purchased 150,000 shares of ProQR Therapeutics stock in a transaction that occurred on Friday, July 17th. The stock was acquired at an average cost of $1.72 per share, with a total value of $258,000.00. Following the acquisition, the director directly owned 300,000 shares in the company, valued at $516,000. This trade represents a 100.00% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders purchased 600,000 shares of company stock valued at $988,500. 8.40% of the stock is owned by company insiders.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.